BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30261494)

  • 1. Role of SIRT2 in Regulation of Stemness of Cancer Stem-Like Cells in Renal Cell Carcinoma.
    Wei R; He D; Zhang X
    Cell Physiol Biochem; 2018; 49(6):2348-2357. PubMed ID: 30261494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma.
    Xiao W; Gao Z; Duan Y; Yuan W; Ke Y
    J Exp Clin Cancer Res; 2017 Mar; 36(1):41. PubMed ID: 28279221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3 promotes CXCR2 to augment the stem-like property of renal cell carcinoma.
    Huang CS; Tang SJ; Lee MH; Chang Wang CC; Sun GH; Sun KH
    J Cell Mol Med; 2018 Dec; 22(12):5909-5918. PubMed ID: 30246456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells.
    Zhong Y; Guan K; Guo S; Zhou C; Wang D; Ma W; Zhang Y; Li C; Zhang S
    Cancer Lett; 2010 Dec; 299(2):150-60. PubMed ID: 20846785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.
    Gassenmaier M; Chen D; Buchner A; Henkel L; Schiemann M; Mack B; Schendel DJ; Zimmermann W; Pohla H
    Stem Cells; 2013 Aug; 31(8):1467-76. PubMed ID: 23630186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells.
    Khan MI; Czarnecka AM; Lewicki S; Helbrecht I; Brodaczewska K; Koch I; Zdanowski R; Król M; Szczylik C
    PLoS One; 2016; 11(11):e0165718. PubMed ID: 27812180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.
    Cheng B; Yang G; Jiang R; Cheng Y; Yang H; Pei L; Qiu X
    Oncotarget; 2016 Oct; 7(40):65862-65875. PubMed ID: 27588469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flotillin-1 expression in human clear-cell renal cell carcinoma is associated with cancer progression and poor patient survival.
    Zhang Y; Li J; Song Y; Chen F; Pei Y; Yao F
    Mol Med Rep; 2014 Aug; 10(2):860-6. PubMed ID: 24913320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
    Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ecto-5'-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells.
    Song L; Ye W; Cui Y; Lu J; Zhang Y; Ding N; Hu W; Pei H; Yue Z; Zhou G
    Oncotarget; 2017 May; 8(19):31977-31992. PubMed ID: 28404888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation.
    Wang L; Park P; La Marca F; Than KD; Lin CY
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1013-24. PubMed ID: 25431339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma.
    Saeednejad Zanjani L; Madjd Z; Abolhasani M; Andersson Y; Rasti A; Shariftabrizi A; Asgari M
    Exp Mol Pathol; 2017 Oct; 103(2):218-228. PubMed ID: 29050853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma.
    Saeednejad Zanjani L; Madjd Z; Abolhasani M; Shariftabrizi A; Rasti A; Asgari M
    Cancer Biomark; 2018; 21(4):821-837. PubMed ID: 29286924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-33 Predicts Poor Prognosis and Promotes Renal Cell Carcinoma Cell Growth Through its Receptor ST2 and the JNK Signaling Pathway.
    Wu CW; Wu YG; Cheng C; Hong ZD; Shi ZM; Lin SQ; Li J; He XY; Zhu AY
    Cell Physiol Biochem; 2018; 47(1):191-200. PubMed ID: 29763892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of reptin in renal cell carcinoma contributes to tumor malignancies and its inhibition triggers senescence of cancer cells.
    Ren J; Li W; Liu H; Yan L; Jiao W; Li D; Tang Y; Gu G; Xu Z
    Urol Oncol; 2013 Oct; 31(7):1358-66. PubMed ID: 22341977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WWOX protein expression varies among RCC histotypes and downregulation of WWOX protein correlates with less-favorable prognosis in clear RCC.
    Lin JT; Tzai TS; Liao CY; Wang JS; Wu TT; Wang HY; Wu CH; Yu CC; Lu PJ
    Ann Surg Oncol; 2013 Jan; 20(1):193-9. PubMed ID: 22555346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of SIPL1 screened by suppression subtractive hybridization (SSH) on biological function and drug resistance of renal cell carcinoma cells].
    Li CY; Yao AM; Chang XN; Guo YH; Xu R
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):897-903. PubMed ID: 24506958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogene miR-154-5p regulates cellular function and acts as a molecular marker with poor prognosis in renal cell carcinoma.
    Lin C; Li Z; Chen P; Quan J; Pan X; Zhao L; Zhou L; Lai Y; He T; Xu W; Xu J; Guan X; Li H; Yang S; Hu Y; Lai Y
    Life Sci; 2018 Sep; 209():481-489. PubMed ID: 30138594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silent information regulator 2 promotes clear cell renal cell carcinoma progression through deacetylation and small ubiquitin-related modifier 1 modification of glucose 6-phosphate dehydrogenase.
    Ni Y; Yang Z; Agbana YL; Bai H; Wang L; Yang L; Yi Z; Cheng J; Zhang Q; Kuang Y; Zhu Y
    Cancer Sci; 2021 Oct; 112(10):4075-4086. PubMed ID: 34310804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
    Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
    Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.